299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000378-30-GB
(EUCTR)
03/03/202026/06/2019A dose finding study of OligoG in patients with CF.A randomised, double-blind, dose finding study of inhaled alginate oligosaccharide (OligoG) vs placebo in patients with Cystic Fibrosis (CF). Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: OligoG CF-5/20 - 17.5 mg
INN or Proposed INN: OLIGOG CF-5/20
Other descriptive name: OLIGOG CF-5/20
Product Name: OligoG CF/20 - 27.5 mg
INN or Proposed INN: OLIGOG CF-5/20
Other descriptive name: OLIGOG CF-5/20
Product Name: OligoG CF/20 - 37.5 mg
INN or Proposed INN: OLIGOG CF-5/20
Other descriptive name: OLIGOG CF-5/20
AlgiPharma ASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
168Phase 2Poland;Ireland;Austria;Germany;United Kingdom
2EUCTR2014-002125-35-DE
(EUCTR)
18/12/201421/07/2014A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp.A randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OligoG) for 28 days in subjects with Cystic Fibrosis using aztreonam due to chronic colonization with Burkholderia spp. - A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp. Cystic Fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: OligoG CF-5/20
INN or Proposed INN: Oligomer of Sodium Alginate
Other descriptive name: OLIGOG CF-5/20
Algipharma ASNULLNot RecruitingFemale: yes
Male: yes
12Phase 2Germany
3EUCTR2014-000844-13-SE
(EUCTR)
21/10/201421/07/2014A phase IIb study of OligoG in subjects with cystic fibrosisA double-blind, randomized, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis. - A phase IIb study of OligoG in subjects with cystic fibrosis Cystic Fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: OligoG CF-5/20
INN or Proposed INN: Oligomer of Sodium Alginate
Other descriptive name: OLIGOG CF-5/20
Algipharma ASNULLNot RecruitingFemale: yes
Male: yes
76Phase 2Denmark;Germany;Sweden
4EUCTR2014-000844-13-DK
(EUCTR)
25/09/201408/07/2014A phase IIb study of OligoG in subjects with cystic fibrosisA double-blind, randomized, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis. - A phase IIb study of OligoG in subjects with cystic fibrosis Cystic Fibrosis
MedDRA version: 17.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: OligoG CF-5/20
INN or Proposed INN: Oligomer of Sodium Alginate
Other descriptive name: OLIGOG CF-5/20
Algipharma ASNULLNot RecruitingFemale: yes
Male: yes
76Phase 2Denmark;Germany;Sweden
5NCT01991028
(ClinicalTrials.gov)
April 201418/11/2013A Study to Investigate Lung Deposition of Radiolabelled OligoGAn Open Label, Randomised, Two-way Crossover Scintigraphic Study to Investigate Lung Deposition of Radiolabelled OligoG Delivered as a Dry Powder and as a Nebulised Solution in Cystic Fibrosis PatientsCystic FibrosisDrug: Radiolabelled OligoG CF-5/20 DPI;Drug: Radiolabelled OligoG CF-5/20 6% SolutionBio-Images Research LtdAlgiPharma ASCompleted18 YearsN/ABoth10Phase 2United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2013-003774-27-GB
(EUCTR)
20/01/201427/11/2013A study to investigate lung deposition of radiolabelled OligoG(v1.0)An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis patients - A study to investigate lung deposition of radiolabelled OligoG (v1.0) Cystic fibrosis (CF) is an autosomal, recessive inheritable disease caused by a homozygote defect at the long arm of Chromosome 7. This mutation causes absence or defect of the cystic fibrosis transmembrane conductance regulator, an ion channel transporting chloride and bicarbonate ions across the cell membrane in exocrine glands. Decreased chloride transport leads to dehydration of the mucus layer, and decreased bicarbonate to increased mucus adhesion. Mucus stagnation results.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: Radiolabelled OligoG CF-5/20 Dry Powder for Inhalation (DPI)
INN or Proposed INN: OligoG
Product Name: Radiolabelled OligoG CF-5/20 6% Solution for Nebulisation
INN or Proposed INN: OligoG
AlgiPharma ASNULLNot RecruitingFemale: yes
Male: yes
12Phase 2United Kingdom
7NCT01465529
(ClinicalTrials.gov)
May 201131/10/2011A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. FibrosisA Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis Chronically Colonised With Pseudomonas AeruginosaCystic FibrosisDrug: OligoG CF-5/20;Drug: SalineAlgiPharma ASNULLCompleted18 YearsN/ABoth26Phase 1;Phase 2Ireland;United Kingdom
8NCT00970346
(ClinicalTrials.gov)
September 20091/9/2009Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic FibrosisA Randomised, Double-blind, Placebo-controlled Dose-escalation Phase I Study to Evaluate the Safety and Tolerability of Inhaled Aerosolised OligoG CF-5/20 (G-block Oligosaccharide Derived From Alginate Polysaccharide) in Healthy VolunteersCystic FibrosisDrug: OligoG CF-5/20AlgiPharma ASSmerud Medical Research International ASCompleted18 Years65 YearsMale26Phase 1United Kingdom
9EUCTR2018-000378-30-PL
(EUCTR)
01/06/2020A dose finding study of OligoG in patients with CF.A randomised, double-blind, dose finding study of inhaled alginate oligosaccharide (OligoG) vs placebo in patients with Cystic Fibrosis (CF). Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: OligoG CF-5/20
INN or Proposed INN: OLIGOG CF-5/20
Other descriptive name: OLIGOG CF-5/20
AlgiPharma ASNULLNAFemale: yes
Male: yes
180Phase 2Poland;Ireland;Austria;Germany;United Kingdom